Study reveals how leukemia cells enter and damage lungs
Led by NYU Langone Health researchers, a new study shows how blood cancer cells enter the lungs, damage tissue and cause severe breathing problems.
Notícias
Acompanhe as Notícias da Recifes
Fique por dentro das últimas novidades sobre tecnologia, negócios e empreendedorismo.
EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic
For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according to a study presented at the annual congress of the E
Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients wit
Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating them with the antibody-drug conju
Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and Drug Administration-appro
Epigenetic mapping provides deeper insight into leukemia
Researchers at Karolinska Institutet in Sweden and Kyoto University in Japan have identified new subgroups of the blood cancer acute myeloid leukemia. The study, published in the journal Nature, shows that changes in the regulation of genes within cells can help explain variation
This unusual epigenetic modifier promotes certain cancers but suppresses others
The epigenetic modifier MLL4 has an unassuming name—the 4, for instance, indicates it's just one in a family of such modifiers. But MLL4 is quite special: In a specific type of leukemia, it drives disease progression, while in solid tumors, it acts as a suppressor.
Inhibiting protein to treat myeloproliferative neoplasms shows preclinical promise
Inhibiting menin, a protein that supports leukemia growth and is already targeted to treat some forms of leukemia, also holds promise for treating myeloproliferative neoplasms. A new study from scientists at St. Jude Children's Research Hospital showed that inhibiting menin signi
Epigenetic therapy shows promise against treatment-resistant AML
Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) by activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth
Study finds obesity 'fuels' leukemia, but a combo using popular weight-loss drugs may stop
Obesity can act as fuel for leukemia, according to a study led by Indiana University School of Medicine scientists. To help patients facing aggressive blood cancers overcome this metabolic risk, researchers identified a potential treatment strategy that combines popular weight-lo
Researchers uncover new therapeutic vulnerability in one of the most aggressive childhood
An international team led by the Josep Carreras Leukaemia Research Institute (IJC) in Barcelona, the Centre for Genomics and Oncological Research (GENyO) and the University of Granada (UGR) has identified a new biological vulnerability in one of the most aggressive forms of child